GlobalData on MSN3d
CStone doses first subject in trial of CS2009 for advanced solid tumours
The antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.
Contract Pharma7d
FDA Approves Fapon Biopharma’s FP008 Cancer Therapy IND Application
The U.S. Food and Drug Administration (FDA) has approved Fapon Biopharma’s Investigational New Drug (IND) application for ...
Cambridge Independent7d
Progress for Microbiotica with UC drug
The update was delivered at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February ...
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...
Thyroid Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, Companies by DelveInsight
Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with ...
Hosted on MSN1mon
BIAL’s first subject completes full dose regimen in Parkinson’s treatment trial
This drug is being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene (GBA-PD ... potentially disease-modifying mechanism of action, with the potential to delay clinical motor ...